Eisai Seeks Global Approval For Cancer Agent Eribulin As Aricept Patent Expiration Looms
This article was originally published in The Pink Sheet Daily
Executive Summary
Eisai has found a combination of efficiency models and belt-tightening - along with a pretty aggressive push to establish an oncology franchise - to realize growth after 2011.